<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02115230</url>
  </required_header>
  <id_info>
    <org_study_id>IncorRDN-ICFEN</org_study_id>
    <nct_id>NCT02115230</nct_id>
  </id_info>
  <brief_title>Renal Denervation in Patients With Heart Failure With Normal LV Ejection Fraction</brief_title>
  <official_title>Transcatheter Renal Denervation in Heart Failure With Normal Left Ventricular Ejection Fraction - a Safety and Efficacy Study of Irrigated Radiofrequency Catheter</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InCor Heart Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>InCor Heart Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is a randomized prospective controlled study of transcatheter renal denervation in
      patients with Heart Failure With Normal LV Ejection Fraction. The purpose of the study is to
      evaluate the safety and effectiveness of renal denervation in patients with Heart Failure
      With Normal LV Ejection Fraction, due to reduction in renal and systemic sympathetic
      activity.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2014</start_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy: Change from baseline E/E' on echocardiography at 12 months</measure>
    <time_frame>12 months after treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety: Composite of death, myocardial infarction, cerebrovascular event, need of intervention on renal arteries and renal function impairment (decrease in estimated GFR &gt; 30% from baseline)</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline E/E' on echocardiography at 6 months</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of office blood pressure and ambulatory blood pressure monitoring (ABPM) between baseline and 12 months</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in any echocardiographic diastolic parameter between baseline and 12 months</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 6 min walking distance between baseline and 12 months</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life (Minnesota Living with Heart Failure Questionnaire) between baseline and 12 months</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum B-type natriuretic peptide (BNP) between baseline and 12 months</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in peripheral sympathetic activity measured by microneurography between baseline and 12 months</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in non-invasive hemodynamic parameters provided by Finometer between baseline and 12 months</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in renal function (GFR, albuminury and 24h urinary Na excretion) between baseline and 12 months</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Heart Failure, Diastolic</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Renal denervation + medical therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Renal sympathetic denervation with an irrigated radiofrequency catheter with Celsius Thermocool (Biosense Webster, California, USA) + standard optimized medical therapy for diastolic heart failure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medical therapy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard optimized medical therapy for diastolic heart failure</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Renal denervation + medical therapy</intervention_name>
    <description>Renal denervation + medical therapy Renal sympathetic denervation with an irrigated radiofrequency catheter with Celsius Thermocool (Biosense Webster, California, USA) + standard optimized medical therapy for diastolic heart failure</description>
    <arm_group_label>Renal denervation + medical therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hypertension treated with at least 2 antihypertensive drugs;

          -  Heart failure with a normal LV ejection fraction;

          -  Left Ventricular Hypertrophy (LV mass index &gt; 96 g/m2 in women and &gt; 116 g/m2 in men);

          -  ≥ 18 years of age;

        Exclusion Criteria:

          -  Known secondary cause of hypertension

          -  Uncontrolled blood pressure (≥ 180x110mmHg)

          -  Unsuitable anatomy of renal arteries, renal stenosis or previous treatment with
             balloon or stent

          -  Advanced renal insufficiency (estimated glomerular filtration rate (GFR) &lt; 30
             ml/min/1.73 square meters)

          -  Diabetes Mellitus type 1

          -  Acute coronary syndrome or a cerebrovascular accident in the last 6 months

          -  Known other cause of respiratory dysfunction

          -  Previous LV systolic dysfunction (LVEF &lt; 50%)

          -  Restrictive cardiomyopathy or Hypertrophic cardiomyopathy

          -  Significant valvar dysfunction

          -  Atrial flutter or atrial fibrillation

          -  Use of the oral anticoagulants

          -  Drug and Alcohol dependence
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pedro A Lemos, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Heart Institute - InCor. University of Sao Paulo Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Heart Institute - InCor. University of Sao Paulo Medical School</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <zip>05403-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Pereira</last_name>
      <phone>+55 11 2661-5368</phone>
      <email>patricia.pereira@incor.usp.br</email>
    </contact>
    <investigator>
      <last_name>Pedro Lemos, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2014</study_first_submitted>
  <study_first_submitted_qc>April 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2014</study_first_posted>
  <last_update_submitted>April 13, 2014</last_update_submitted>
  <last_update_submitted_qc>April 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>InCor Heart Institute</investigator_affiliation>
    <investigator_full_name>Pedro A. Lemos</investigator_full_name>
    <investigator_title>Pedro A. Lemos, Professor of Medicine, InCor Heart Institute</investigator_title>
  </responsible_party>
  <keyword>Heart Failure</keyword>
  <keyword>Heart Failure, Diastolic</keyword>
  <keyword>Hypertension</keyword>
  <keyword>Renal Denervation</keyword>
  <keyword>Irrigated Radiofrequency Catheter</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Heart Failure, Diastolic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

